Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeuticsin 2019
According to our new market research study on “EuropeRNAi Therapeutics Marketto 2027 – Regional Analysis and Forecast – by Molecule Type,Route of Administration, Application, and End User”the Europe RNAi therapeutics market is expected to reach US$ 324.33 million in 2027 from US$ 170.42 million in 2019, it is estimated to grow with a CAGR of 8.4% from 2020-2027. The report provides trends prevailing in the EuropeRNAi therapeutics market and the factors driving the market growth along with those hindering it.
In 2019, the small interfering RNAs (siRNA) accounted for the highest share of the market. Growth of this segment is attributed to the increasing preference for small interfering RNAs for drug development and growing number of research partnerships. Furthermore, MicroRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.
The growth of the EuropeRNAi therapeuticsmarketis mainly attributed togrowing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and its benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region will eventually drive the market growth.However,the high cost of RNAi therapy development is the major factor hindering the market growth in Europe.
Sanofi;GlaxoSmithKline plc; Silence Therapeutics;Alnylam Pharmaceuticals, Inc; andArrowhead Pharmaceuticals, Incare among the leading companies operating in the EuropeRNAi therapeuticsmarket.
Europe RNAi Therapeutics Market, By Country, 2019 (%)
Europe RNAi Therapeutics Market to Grow at a CAGR of 8.4% to reach US$ 324.33 million from 2020 to 2027
Download Free Sample
Europe RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) Geography
Europe RNAi Therapeutics Market to Grow at a CAGR of 8.4% to reach US$ 324.33 million from 2020 to 2027
Download Free SampleEurope RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) Geography
The Report Segments Europe RNAi Therapeutics Market as Follows:
Europe RNAi Therapeutics Market– By MoleculeType
- Small Interfering RNAs (siRNA)
- MicroRNA (miRNA)
Europe RNAi Therapeutics Market – ByRoute of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intradermal Injections
- Intraperitoneal Injections
- Others
Europe RNAi Therapeutics Market – By Application
- Oncology
- Cardiovascular
- Respiratory Disorders
- Renal Diseases
- Genetic Disorders
- Neurodegenerative Disorders
- Infectious Diseases
- Others
Europe RNAi Therapeutics Market – By End User
- Research and Academic Laboratories
- Hospitals
- Diagnostic Laboratories
Europe RNAi Therapeutics Market– By Country
- Europe
- Germany
- UK
- France
- Italy
- Spain
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com